RGD-PET in Kidney Cancer angiogenesis
Research type
Research Study
Full title
Prospective study of 18F-RGD PET-CT in assessment of response to antiangiogenic treatment in patients with renal cancer and comparison with perfusion CT
IRAS ID
104668
Contact name
Fergus Gleeson
Sponsor organisation
Oxford University Hospitals NHS Trust
Eudract number
2011-002833-20
Clinicaltrials.gov Identifier
Research summary
Cancer cells develop their own blood supply in order to grow and spread. The process involved in the development of a new blood supply is called angiogenesis. It is thought that the amount of new blood vessel development relates to the aggressiveness of the cancer. There is a lot of research at present into new cancer treatments which target angiogenesis in tumours. It would be useful to measure new blood vessel development in order to determine which patients have aggressive tumours, and also those who are likely to benefit from drugs targeting angiogenesis. Our standard imaging techniques do not provide us with much information on the blood supply in the cancer. At present the only way to measure blood vessel development in tumours accurately is to take a sample of the tumour and look at it under the microscope. The goal of this clinical research study is to look at 2 new methods of scanning and see whether they can help researchers predict which tumours will respond to drugs that are used to attack the blood supply to the tumour. These scanning agents will be used in patients with renal cell carcinoma (RCC). They will be used to assess whether we can see changes in this type of tumours between before and after treating with an antiangiogenic therapy. It is hoped that the changes seen will help identify the patients who will respond to treatment.
REC name
South Central - Oxford B Research Ethics Committee
REC reference
12/SC/0376
Date of REC Opinion
20 Aug 2012
REC opinion
Further Information Favourable Opinion